Chinese Device Maker Mindray Expertly Navigates Global Healthcare Currents While Profits Soar
BEIJING - China's leading medical device developer, Mindray Medical International, reprised its role as one of the region's most adept navigators of the shifting currents of global demand in the healthcare sector as it posted a double-digit rise in net earnings for the third quarter despite the worldwide financial maelstrom
More from Archive
More from Scrip
Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.
A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.